There were no significant differences in any-grade and high-grade toxicities between the PD-1 and PD-L1 inhibitor groups, except for any-grade pneumonitis (15.20% vs 4.88%, p=0.03) and high-grade leukopenia (6.25% vs 59.09%, p=0.00). The gene discussed is PDCD1; the disease is pneumonitis.